STAT2-Defective Mutant Daudi (RST2) cell line
Invented by Dr. Lawrence Pfeffer
Invented at The University of Tennessee Health Science Center
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 156502 |
| Parental Line | Human Daudi Burkitt Lymphoma cell line |
| Host | Human |
| Tissue | Blood |
| Disease Keywords | Burkitt lymphoma |
| Model | Transgenic |
| Relevance | This cell line can be used to study drug resistance developed after treatment with interferon. Interferon therapy has been proved as a successful treatment for various types of cancer, however it develops resistance in patients. This cell line was not affected by the antiviral, antiproliferative, and gene-inducing actions of IFN. |
| Production Details | Isolated from IFN-sensitive Daudi cell line by growth in the continuous presence of IFN |
| Research Area | Cancer |
| Recommended Growing Conditions | RPMI1640 and 10% defined calf serum; Subculture 1:4 twice a week, maintain 1 and 10X10^5 cells/mL |
References: 2 entries
Schmeisser et al. 2013. Autophagy. 9(5):683-96. PMID: 23419269.
Du et al. 2009. J Biol Chem. 284(41):27808-15. PMID: 19687011.
Add a reference
References: 2 entries
Schmeisser et al. 2013. Autophagy. 9(5):683-96. PMID: 23419269.
Du et al. 2009. J Biol Chem. 284(41):27808-15. PMID: 19687011.
Add a reference
Inventor Information
Inventors
|
Dr. Lawrence Pfeffer |
